Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 18/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1909096 | 0.90 | MAPKAPK2 (0.75) | MAPKAPK2 | |
| SCHEMBL1909074 | 0.88 | MAPKAPK2 (0.64) | MAPKAPK2RET | |
| SCHEMBL1909018 | 0.88 | MAPKAPK2 (0.73) | MAPKAPK2 | |
| SCHEMBL1909051 | 0.82 | MAPKAPK2 (0.57) | MAPKAPK2 | |
| SCHEMBL1909308 | 0.80 | MAPKAPK2 (0.60) | MAPKAPK2 | |
| SCHEMBL1908848 | 0.79 | MAPKAPK2 (0.40) | MAPKAPK2 | |
| SCHEMBL1909221 | 0.78 | MAPKAPK2 (1.00) | MAPKAPK2 | |
| SCHEMBL1909070 | 0.77 | MAPKAPK2 (0.76) | MAPKAPK2 | |
| SCHEMBL1908930 | 0.77 | MAPKAPK2 (1.00) | MAPKAPK2 | |
| SCHEMBL1909285 | 0.76 | MAPKAPK2 (0.71) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | MAPKAPK2 480/4885RET 993/4885KDM1A 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.